Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$1.41
EPS est.
$1.23
EPS surprise
+14.63%
1-day move
-3.32%
Revvity, Inc. reported stronger-than-expected earnings per share, beating the consensus by 14.63%. However, the stock reacted negatively, declining by 3.32%. The lack of revenue information and guidance may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.41 | $1.22 | +14.63% |
| Revenue | — | $703M | — |
No transcript is on record, and the analysis is based on numerical results only.
Revvity, Inc. operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in advancing research and development in the life sciences, which is increasingly important as the industry seeks innovative solutions and efficiencies.
Last quarter
In Q1 2026, Revvity reported an EPS of $1.04, beating estimates by 2.16%. The stock reacted positively, gaining 6.69% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+6.91%
Avg 1-day reaction
-0.61%
Analysts expect Revvity to report strong earnings, with a consensus EPS of $1.22 and revenue of $703M. The market is watching closely for any signs of growth or challenges.
Bull case
If Revvity exceeds EPS estimates, it could signal strong demand for its products and services, leading to increased investor confidence and a potential stock price rally.
Bear case
Conversely, if the company falls short of expectations, it may raise concerns about its growth trajectory and market position, potentially leading to a decline in stock value.
Key metrics to watch
EPS
$1.22Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.
Revenue
$703MRevenue growth reflects the company's ability to expand its market presence and meet customer demand.
The print will turn on these.
Q1
Will Revvity's EPS exceed the consensus estimate of $1.22?
A beat on EPS would reinforce the company's growth narrative and could lead to a positive market reaction.
Q2
What specific revenue growth figures will Revvity report?
Revenue performance is critical for assessing the company's market position and future growth potential.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate Revvity's ability to leverage new technologies in life sciences, which could drive higher-than-expected revenue growth.
Supporting evidence
The company's recent innovations in life sciences tools have not been fully reflected in analyst models.
Options pricing suggests a larger move than historical averages, indicating potential surprises.
Past performance shows consistent EPS beats, suggesting a trend that may continue.
Key risk
If Revvity's revenue growth exceeds $706M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will be pivotal in determining investor sentiment and future growth expectations.
Bull confirmed if
An EPS of $1.25 or higher would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $1.19 would raise concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±5.73%
Historical Avg
±3.3%
The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.
Options are pricing ±5.7% while RVTY has averaged ±3.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
50.1%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$13,060.32
84 sh
1 insider
Net
$13,060.32
Net selling
Most Active Insiders· 1 open-market trade
$13,060.32
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
96.61%
of float
Insider
0.26%
of float
Holders
769
institutions
Top Holders· as of Jun 2026
T. Rowe Price Investment Management, Inc.
18,261,177 sh · $2.8B
16.37%
-17.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Revvity beats expectations, history suggests a potential stock increase of around 0.94%, confirming strong operational performance.
In line / cautious
An inline report may lead to muted reactions, as investors await further clarity on growth strategies.
Miss
If the company misses expectations, the stock could decline, with historical patterns indicating a potential drop of around 0.94%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
2 buys·0 sells
Members
1
House only
Est. Notional
$16,002.00–$65,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $155.48
84 sh
$13,060.32
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Jupiter Topco LLC
8,637,614 sh · $1.3B
7.74%
100.0%
Edgepoint Investment Group Inc.
8,544,479 sh · $1.3B
7.66%
-2.9%
Blackrock Inc.
7,658,369 sh · $1.2B
6.86%
5.6%
Vanguard Capital Management LLC
7,300,973 sh · $1.1B
6.54%
-0.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 4, 2026 · disclosed Jun 8, 2026
$15,001.00–$50,000.00
Traded May 1, 2026 · disclosed May 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.